M. Golam Mohi - Concepedia

Author

M. Golam Mohi

Beth Israel Deaconess Medical Center

Also Known As

M G Mohi, M Golam Mohi, M. Golam Mohi, M.Golam Mohi, Mohammad Golam Mohi

Publications

Citations

H-Index

Concepts

All Affiliations

Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard University The University of Tokyo

About

M. Golam Mohi is an author at Beth Israel Deaconess Medical Center specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	971
2	Cell Biology	5	5	971
3	Health Sciences	1	1	14
4	Natural Sciences	1	1	26
5	Immunology	1	1	14

M. Golam Mohi

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation Toshiyuki Araki, M. Golam Mohi, Fraz A. Ismat, Nature Medicine Ptpn11 MutationGenetic DisorderGeneticsNoonan Syndrome RevealsGene Function	2004	417
Critical role for Gab2 in transformation by BCR/ABL Martin Sattler, M. Golam Mohi, Yuri B. Pride, Cancer Cell Ab-initio MethodCritical RoleMolecular Biology	2002	358
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations M. Golam Mohi, Ifor R. Williams, Charles R. Dearolf, Cancer Cell Knockout MouseGenome InstabilitySignal TransductionMixed-phenotype Acute LeukemiaSystems Biology	2005	275
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like disease Hajime Akada, Dongqing Yan, Haiying Zou, Blood	2010	243
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs M. Golam Mohi, Christina Boulton, Ting‐Lei Gu, Proceedings of the National Academy of Sciences Ptk Inhibitor/rapamycin CombinationsMixed-phenotype Acute LeukemiaMtor Inhibitor RapamycinTumor BiologyMyeloid Neoplasia	2004	239
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis Gordon Chan, Demetrios Kalaitzidis, Tatiana Usenko, Blood	2009	120
Activation and Functional Analysis of Janus Kinase 2 in BA/F3 Cells Using the Coumermycin/Gyrase B System M. Golam Mohi, Ken‐ichi Arai, Sumiko Watanabe Molecular Biology of the Cell	1998	39
Phosphatidylinositol 3-Kinase p85α Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences Shuyue Ren, Elisabeth Bolton, M. Golam Mohi, Molecular and Cellular Biology Bcr/abl-related Fusion TyrosineMolecular RegulationApoptosisMolecular BiologyP85alpha Subunit	2005	26
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer David Masiello, M. Golam Mohi, Nicole C. McKnight, Cancer Biology & Therapy	2007	22
Analysis of mechanisms involved in the prevention of γ irradiation-induced apoptosis by hGM-CSF Rui Liu, Chang-Bai Liu, M. Golam Mohi, Oncogene Radiation MedicineRadiation BiologyRadiation PhysicsApoptosisImmunology	2000	14

Page 1